Normunity is a clinical-stage biotechnology company developing novel anti-cancer therapies that work at the interface of the immune system and the tumor. In collaboration with the Lieping Chen lab at the Yale School of Medicine, Normunity has identified a novel class of "Immuno-smart targets" — tumor-specific, cell-surface proteins co-opted by… - View it on GitHub